Outcomes of Patients with Metastatic Melanoma—A Single-Institution Retrospective Analysis

SIMPLE SUMMARY: Approximately 15% of patients diagnosed with locally advanced malignant melanoma will relapse. Currently, anti-PD-1 and anti-CTLA4 antibodies and BRAF/MEK inhibitors are the mainstay of treatment of advanced, inoperable or disseminated malignant melanoma. A group of 52 patients treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Szatkowska, Lidia, Sieczek, Jan, Tekiela, Katarzyna, Ziętek, Marcin, Stachyra-Strawa, Paulina, Cisek, Paweł, Matkowski, Rafał
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997072/
https://www.ncbi.nlm.nih.gov/pubmed/35406444
http://dx.doi.org/10.3390/cancers14071672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997072/
https://www.ncbi.nlm.nih.gov/pubmed/35406444
http://dx.doi.org/10.3390/cancers14071672

Ejemplares similares